Why Yale Urology
At Yale Urology, we understand that a diagnosis of prostate cancer can profoundly impact your life and leave you and your loved ones with many questions about your journey ahead. Our team members are dedicated to providing the compassionate care, support, and information you need to move forward confidently with your treatment process.
Yale Prostate and Urologic Cancers Program at Yale Cancer Center offers a multidisciplinary, comprehensive approach to treating urologic malignancies. We are committed to offering our patients with early- and late-stage prostate cancer the most advanced diagnostic technologies and treatment strategies available.
At Yale Urology, we are committed to helping men with prostate cancer by using leading-edge and minimally invasive procedures wherever possible.
The Artemis Device uses proprietary, next-generation, 3D technology. This innovative device lets doctors virtually see inside the prostate while performing a prostate biopsy. As a result, the accuracy in performing biopsies is greatly increased, which helps to improve the diagnosis and manage the progression of prostate cancer.
Because many prostate cancers advance slowly, not all patients need to undergo surgery to remove suspicious cells. Our Active Surveillance program uses advanced imaging and real-time ultrasound to monitor and biopsy suspicious lesions, removing the need for surgery for many patients who have a low-grade form of prostate cancer.
Using the most advanced, minimally-invasive techniques such as robotic-assisted surgery, our surgeons can personalize their approach to treating prostate cancer. Minimally invasive and robotic-assisted surgeries performed by our surgeons include nerve-sparing prostatectomy and laparoscopic and robotic-assisted laparoscopic prostatectomy.
Our team is at the forefront of research for prostate cancer in areas such as diagnostic imaging, active surveillance, and high-risk prostate cancer. Our surgeons continually integrate the latest in science-based medicine and innovative approaches into their practice to offer patients safer and more effective treatments.
About Prostate Cancer
Prostate cancer is the most common non-skin cancer among men in the United States. Located just below the bladder, the prostate is a gland responsible for producing and storing fluid that helps make semen, and it is also involved in regulating bladder control.
Prostate cancer tends to be slow growing and in many cases, may go undetected. Some forms of prostate cancer, however, can be more aggressive and spread quickly. Early detection plays a critical role in increased five-year survival rates.
The most common cell type of prostate cancer is adenocarcinoma, and is the second most common cancer among men over 65. Other cell types of prostate cancer include small cell, squamous cell, and other rare cell types, all of which generally require more aggressive cancer treatment than adenocarcinomas.
to learn about clinical trials currently going on at Yale.
For additional information about prostate cancer from the National Cancer Institute: